Allison Perry

By

College: Arts and Sciences

Glazer Receives Grant to Study Light-Activated Cancer Drugs

Published: Jan 31, 2013

LEXINGTON, Ky. (Jan. 31, 2013) — University of Kentucky assistant professor of chemistry Edith "Phoebe" Glazer has received an American Cancer Society Research Scholar Grant for $715,000 over four years to continue her research into ruthenium-based cancer drugs. These compounds are less toxic to healthy cells than a similar and widely used inorganic drug.

 

Cisplatin is a common platinum-based cancer drug used in a variety of cancer treatments. But while cisplatin kills cancer cells, it also attacks healthy cells, causing debilitating side effects. Ruthenium is another transition metal and belongs to the same group of the periodic table as iron.

 

Previously, the Glazer group developed two new ruthenium complexes designed to kill cancer cells while preserving healthy cells. These complexes are inert in the dark, but when activated with light, they become up to 200 times as toxic, and up to three times as potent as cisplatin against tumor cells.

 

Funded by the American Cancer Society, the new grant will allow Glazer's team to develop improved ruthenium-based compounds and to study their effectiveness. Using the strategy of combining organic ligands as building blocks that assemble around the ruthenium center “core,” a large family of compounds with different structures and properties can be rapidly synthesized. This is in marked contrast to approaches using compounds discovered in nature, called natural products, as chemotherapeutics.

 

Many chemotherapeutics are natural products, but their synthesis is challenging and there are limited chemical modifications that can be made into the molecules. In the ruthenium compounds, the organic components can be easily changed to alter chemical properties and possibly even what types of cells the compounds will enter in the body. The different structures can also potentially prevent the development of drug resistance, as tumors that become resistant to one particular ruthenium drug structure could be vulnerable to another ruthenium compound with a different structure. 

 

The efficacy of the compounds will be tested in different human cancer cell lines and in animal models to determine what cancer types can be treated. The group will also determine the biochemical process by which the compounds kill cells in order to optimize the drugs. The long-term goal of the research is to develop a targeted chemotherapeutic approach with reduced side effects that can be applied to a variety of cancer types.

 

MEDIA CONTACT: Allison Perry, (859) 323-2399 or allison.perry@uky.edu

microscope_closeup_1.jpg
December
 
1
Resumes and Cover Letters
Circle of Love Gift Return
Mon
2
UK Guitar Studio
Circle of Love Gift Return
Tue
3
Networking and Job Search
Internship Info Session
LNFS Presents: Wayne's World
Study Sounds: Classical Concert
Wed
4
LNFS Presents: Frozen
Ballet Music of Tchaikovsky
Circle of Love Gift Pick-Up
Live Screening of Orion Spacecraft Re-entry
Massage on the Go
Thu
5
LNFS Presents: Winter's Bone
LNFS Presents: Gremlins
Open Studio
Circle of Love Gift Pick-Up
Fri
6
Snow Skiing @ Perfect North Slopes
Sat
7
Free Holiday Shopping Shuttle to Fayette Mall
Sun
8
Undergraduate Research Information Session "How to Find a Faculty Mentor"
Mon
9
Job Club - Identifying Your Skills
Paws for Stress Relief
Tue
10
 
Wed
11
 
Thu
12
Last Day of Classes
Fri
13
 
Sat
14
Free Holiday Shopping Shuttle to Fayette Mall
Finals Treats
Sun
15
Final Exams
Crunch Brunch
Mon
16
Final Exams
Jazzy Holiday Concert
Tue
17
Final Exams
Caregiver Support Group
Wed
18
Final Exams
Thu
19
Final Exams
End of 2014 Fall Semester
Fri
20
 
Sat
21
 
Sun
22
 
Mon
23
 
Tue
24
 
Wed
25
 
Thu
26
 
Fri
27
 
Sat
28
 
Sun
29
 
Mon
30
 
Tue
31
 
Wed
 
 
 
Dec 19
End of 2014 Fall Semester 12/19/2014

Wed, 01/14/2015

Fri, 01/16/2015

Wed, 01/21/2015

Reset Page